Logo image
Back
Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas
Journal article   Open access   Peer reviewed

Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas

Shaojun Lin, Qiaojuan Guo, Jiangmei Wen, Chao Li, Jin Lin, Xiaofei Cui, Nianli Sang and Jianji Pan
Journal of experimental & clinical cancer research, v 33(1), pp 26-26
08 Mar 2014
DOI: https://doi.org/10.1186/1756-9966-33-26
PMID: 24606961
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1186/1756-9966-33-26View
Published, Version of Record (VoR)CC BY V4.0,  Open

Abstract

Carcinoma - metabolism Carcinoma - mortality Carcinoma - radiotherapy Carcinoma - secondary Disease-Free Survival Female Gene Expression Glycoproteins - metabolism Humans Intercellular Signaling Peptides and Proteins - metabolism Kaplan-Meier Estimate Male Middle Aged Multivariate Analysis Nasal Mucosa - metabolism Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms - metabolism Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - pathology Nasopharyngeal Neoplasms - radiotherapy Prognosis Retrospective Studies Treatment Outcome
Stanniocalcin 2 (STC2) is overexpressed in several types of human cancers, and its overexpression positively correlates to tumor progression and poor prognosis. However, the clinical significance of STC2 overexpression in nasopharyngeal carcinomas (NPC) has not been investigated. This study examined STC2 expression in a cohort of 94 NPC samples, and explored its value in clinical diagnosis and prognosis. Tumor samples from 94 patients diagnosed in 2008 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be poorly differentiated or undifferentiated NPC without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. Survival analyses were performed. Of the 94 NPC samples, STC2 overexpression (STC2+) was detected in 65 samples (69.1%). Overall survival rate of STC2 (+) patients is significantly lower than that of patients with normal STC2 levels (72.2% vs. 96.4%, respectively, P = 0.049). Moreover, STC2 (+) is also strongly predictive of a low progression-free survival and distant metastasis-free survival (63.0% vs 92.9%. P = 0.007; and 77.0% vs 96.4%. P = 0.028). Of the 54 patients treated with IMRT, residual tumors were found in 54.8% of STC2 positive patients (17/31), but only in 17.4% of STC2 negative ones (4/23), suggesting STC2 overexpression predicts a higher risk of residual tumors after IMRT. STC2 overexpression correlates to poor prognosis for NPC and may be useful as a novel biomarker to predict NPC responses to radiation. Whether STC2 promotes NPC progression and metastasis remains to be investigated.

Metrics

10 Record Views
36 citations in Web of Science
40 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
International collaboration
Web of Science research areas
Oncology
Logo image